Dataset Information


SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials.

ABSTRACT: BACKGROUND:Type 2 diabetes is closely related to an increased risk of atrial fibrillation (AF) and atrial flutter (AFL). Whether sodium-glucose cotransporter 2 (SGLT2) inhibitors can attenuate AF/AFL progression remains unclear. METHODS:We searched electronic databases (PubMed, Embase and ClinicalTrials.gov) from their inception to January 2020 for trials evaluating the AF outcomes of SGLT2 inhibitors in patients with type 2 diabetes. The data search and extraction were conducted with a standardized data form and any conflicts were resolved by consensus. Relative risks (RRs) with 95% confidence intervals (CIs) were used for binary variables, and the weighed mean differences (WMDs) with the standard deviation (SDs) were applied for continuous variables. RESULTS:We included data from 16 identified trials consisting of 38,335 patients with type 2 diabetes. Incorporated data demonstrated that compared to placebo, SGLT2 inhibitors significantly reduced AF/AFL (RR: 0.76; 95% CI 0.65-0.90; p?=?0.001) and all-cause mortality (RR: 0.91; 95% CI 0.83-0.99; p?=?0.03). AF/AFL reductions were not modified by age, body weight, glycated haemoglobin (HbA1c), or systolic blood pressure (SBP) at baseline (all p-interactions?>?0.3). SGLT2 inhibitors also significantly reduced heart failure events (RR: 0.73; 95% CI 0.64-0.84; p?


PROVIDER: S-EPMC7448518 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6778578 | BioStudies
2020-01-01 | S-EPMC7477503 | BioStudies
2019-01-01 | S-EPMC6736944 | BioStudies
2014-01-01 | S-EPMC4277392 | BioStudies
2019-01-01 | S-EPMC6531575 | BioStudies
2020-01-01 | S-EPMC7523512 | BioStudies
2017-01-01 | S-EPMC5490461 | BioStudies
1000-01-01 | S-EPMC6352265 | BioStudies
2017-01-01 | S-EPMC5300230 | BioStudies
2012-01-01 | S-EPMC3488745 | BioStudies